 |
|
Adrenocortical Carcinoma
Surgical Progress or Status Quo?
Michael L. Kendrick, MD;
Ricardo Lloyd, MD;
Lori Erickson, MD;
David R. Farley, MD;
Clive S. Grant, MD;
Geoffrey B. Thompson, MD;
Charles Rowland, MS;
William F. Young, Jr, MD;
Jon A. van Heerden, MD
Arch Surg. 2001;136:543-549.
Hypothesis Outcome of patients with adrenocortical carcinoma (ACC) has improved with the advent of more widely available and higher quality imaging. Operative management strategies and use of adjuvant therapy have not changed.
Design Retrospective review of patient histories, imaging studies, operative data, adjuvant therapy, and outcomes at a single institution. Follow-up was complete for a mean of 53 months. Data was compared with prior institutional experience.
Setting Tertiary care referral center.
Patients All patients undergoing operative management for ACC during the period from 1980 to 1996.
Main Outcome Measures Determinants of recurrence, survival, and the effect of adjuvant therapy on overall outcome.
Results Fifty-eight patients (30 men, 28 women) with a mean age of 53 years underwent primary operative management for ACC. Functional tumors were identified in 27 patients (47%). Mean tumor size was 12.5 cm. Stage according to the TNM staging system (AJCC Cancer Staging Manual) at presentation was I (n = 0), II (n = 30), III (n = 7), and IV (n = 21). Surgical management included curative resection in 41 (71%), noncurative resection in 14 (24%), and open biopsy in 3 (5%). Perioperative mortality was 5%. Recurrence occurred in 30 patients (73%) with a median time to recurrence of 17 months. Five-year survival by the Kaplan-Meier method was 37%. Prognostic factors (P<.05) included functional status, stage, and chemotherapy in stage III/IV patients. When compared with our prior institutional experience (1960-1980), current patients were more likely to present with stages I to II (52% vs 34%), have curative resections (71% vs 50%), and have improved 5-year survival (37% vs 16%).
Conclusions (1) Surgical resection remains the principal treatment for stage I to III disease. (2) Adjuvant therapy may improve survival in patients with stage III or IV disease. (3) Current patients were more likely to present at an earlier stage, undergo curative resections, and have improved 5-year survival than institutional historical comparisons.
From the Departments of Surgery (Drs Kendrick, Farley, Grant, Thompson, and van Heerden), Pathology (Drs Lloyd and Erickson), Endocrinology (Dr Young), and Statistics (Mr Rowland), Mayo Clinic, Rochester, Minn.
RELATED ARTICLE
This Month in Archives of Surgery
Arch Surg. 2001;136(5):498.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.
Hermsen et al.
Eur J Endocrinol 2008;158:911-919.
ABSTRACT
| FULL TEXT
Surgical Outcome of Stage III and IV Adrenocortical Carcinoma
Ohwada et al.
Jpn J Clin Oncol 2007;0:hyl127v1-6.
ABSTRACT
| FULL TEXT
Prognostic Parameters of Metastatic Adrenocortical Carcinoma
Assie et al.
J. Clin. Endocrinol. Metab. 2007;92:148-154.
ABSTRACT
| FULL TEXT
Adrenocortical Carcinoma: Clinical Update
Allolio and Fassnacht
J. Clin. Endocrinol. Metab. 2006;91:2027-2037.
ABSTRACT
| FULL TEXT
Diagnostic and Prognostic Value of 18-Fluorodeoxyglucose Positron Emission Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography
Leboulleux et al.
J. Clin. Endocrinol. Metab. 2006;91:920-925.
ABSTRACT
| FULL TEXT
The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management
Mansmann et al.
Endocr. Rev. 2004;25:309-340.
ABSTRACT
| FULL TEXT
Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma
Baudin et al.
Ann Oncol 2002;13:1806-1809.
ABSTRACT
| FULL TEXT
Signaling Pathways in Adrenocortical Cancer
KIRSCHNER
Ann. N. Y. Acad. Sci. 2002;968:222-239.
ABSTRACT
| FULL TEXT
|
